Nanotech-magnetism combo leads to tiny implantable device for drug delivery

Washington, September 20 (ANI): Combining magnetism with nanotechnology, researchers have developed a small implantable device that can be repeatedly turned on and off to deliver and adjust doses of medications inside a patient's body.

Dr. Daniel Kohane, of Children's Hospital Boston, has revealed that the tiny device encapsulates the drug in a specially engineered membrane, embedded with nanoparticles composed of magnetite, a mineral with natural magnetic properties.

When a magnetic field is switched on outside the body, near the device, the nanoparticles heat up, causing the gels in the membrane to warm and temporarily collapse. This opens up pores that allow the drug to pass through and into the body.

When the magnetic force is turned off, the membranes cool and the gels re-expand, closing the pores back up and halting drug delivery. No implanted electronics are required.

Kohane and colleagues are continuing to develop the device for clinical use.

"A device of this kind would allow patients or their physicians to determine exactly when drugs are delivered, and in what quantities," says Kohane, who directs the Laboratory for Biomaterials and Drug Delivery in the Department of Anesthesiology at Children's.

When the researchers conducted animal experiments, the membranes remained functional over multiple cycles.

The size of the dose was controllable by the duration of the "on" pulse, and the rate of release remained steady, even 45 days after implantation.

Testing indicated that drug delivery could be turned on with only a 1 to 2 minute time lag before drug release, and turned off with a 5 to 10 minute time lag.

The membranes remained mechanically stable under tensile and compression testing, indicating their durability, showed no toxicity to cells, and were not rejected by the animals' immune systems.

They are activated by temperatures higher than normal body temperatures, so would not be affected by the heat of a patient's fever or inflammation.

"This novel approach to drug delivery using engineered 'smart' nanoparticles appears to overcome a number of limitations facing current methods of delivering medicines," says Dr. Alison Cole, who oversees anesthesia grants at the National Institutes of Health's National Institute of General Medical Sciences (NIGMS).

"While some distance away from use in humans, this technology has the potential to provide precise, repeated, long-term, on-demand delivery of drugs for a number of medical applications, including the management of pain," Dr. Cole adds.

A research article describing the device has been published in the journal Nano Letters. (ANI)